GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » YoY EBITDA Growth

Harbin Medisan Pharmaceutical Co (SZSE:002900) YoY EBITDA Growth : -49.08% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Harbin Medisan Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -49.08%.

Harbin Medisan Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.08.


Harbin Medisan Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co YoY EBITDA Growth Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.66 -62.74 384.57 -69.26 23.93

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,616.67 -43.75 28.57 32.81 -49.08

Harbin Medisan Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Harbin Medisan Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.694-0.56)/ | 0.56 |
=23.93 %

Harbin Medisan Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(0.083-0.163)/ | 0.163 |
=-49.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Medisan Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines